HMnO2-DMRT2 Nanomaterials Ameliorate Insulin Resistance by Stabilizing Mitochondrial Dynamics and Remodeling Adipose Tissue
ZHANG Meimei1,2,3, YONG Jiahui2,3, WANG Zijie3,4, WANG Juan2,3, SHEN Xin2,3, ZENG Lu2,3, YANG Yining2,3, TAO Jing2,3*
This study aimed to investigate the therapeutic effects and underlying mechanisms of HMnO2 DMRT2 nanomaterials on HFD (high-fat diet)-induced IR (insulin resistance). Firstly, pH-responsive HMnO2 (hollow manganese dioxide) nanoparticles were synthesized to load the DMRT2 (double sex and Mab-3 related transcription factor 2) gene (HMnO2-DMRT2). The nanomaterials were characterized by TEM (transmission elec tron microscopy), DLS (dynamic light scattering), and XPS (X-ray photoelectron spectroscopy) technology, and cytotoxicity was assessed using CCK-8 (cell counting kit-8) assay. Secondly, for the in vivo experiments, mice were randomly allocated into four groups (n=6 per group): Control group, HFD group, HFD+HMnO2 group, and HFD+HMnO2-DMRT2 group. Glucose metabolism was evaluated by GTT (glucose tolerance test) and ITT (insulin tolerance test). Adipose tissue morphology was examined by HE staining. UCP-1(uncoupling protein 1) protein levels were assessed by IHC (immunohistochemistry). The levels of TNF-α (tumor necrosis factor-α), IL 1β (interleukin-1β), IL-6 (interleukin-6), IL-10 (interleukin-10), and ADP (adiponectin) were measured by ELISA. The protein expression levels of DMRT2, GLUT4 (glucose transporter type 4), AKT (protein kinase B), p-AKT (phosphorylated AKT), UCP-1, and Prdm16 were detected by Western blot. The mRNA expression of Ucp-1 and Prdm16 was detected by qPCR. Finally, in vitro experiments, 3T3-L1 adipocytes were divided into five groups: Control group, IR group, IR+HMnO2 group, IR+DMRT2 group, and IR+HMnO2-DMRT2 group. Glucose uptake was measured using the 2-DG uptake assay. SOD (superoxide dismutase) activity, GSH (glutathione), and MDA (malondialdehyde) levels were detected using commercial kits. Mitochondrial ROS (reactive oxygen species) levels were detected using MitoSOX Red staining. The protein expression levels of DMRT2, MFN1/2 (mitofusin 1/2), op tic atrophy protein 1 (OPA1), OMA1 (OMA1 zinc metallopeptidase), Drp1 (dynamin related protein 1), and p-Drp1 (phosphorylated Drp1) were detected by Western blot. Characterization results indicated that the HMnO2-DMRT2 nanoparticles maintained an intact morphology without significant aggregation. Particle size analysis revealed an inner diameter of approximately (103.50±28.04) nm. The nanoparticles were composed of O (oxygen), Mn (man ganese), and C (carbon) elements, with a Zeta potential of (–16.20±9.66) mV. The encapsulation efficiency was 85.78%±3.01%, and the drug loading capacity was 7.73%. Furthermore, the release rate of DMRT2 plasmid from the nanoparticles was significantly faster at pH5.5 than at pH7.4. CCK-8 assay results showed no significant dif ferences in cell viability among the groups, indicating that the HMnO2-DMRT2 nanomaterials possess no obvious cytotoxicity in vitro. In vivo experimental results demonstrated that, compared to the HFD group, the HFD+HMnO2 group showed no significant change in body weight at weeks 6 and 9, but exhibited a significant decrease in fast ing blood glucose levels and AUC (area under the curve), along with a significant increase in GLUT4 and p-AKT protein expression (P<0.001). However, adipocytes size remained markedly increased, with some inflammatory cell infiltration observed, and there were no significant changes in the mRNA and protein expression levels of UCP 1 and Prdm16. In contrast, mice in the HFD+HMnO2-DMRT2 group experienced weight loss (P<0.05), a signifi cant increase in glucose uptake levels, a significant reduction in fasting blood glucose levels and AUC. The mRNA and protein expression levels of the brown fat-related genes UCP-1 and Prdm16 were both significantly increased (P<0.001). Moreover, adipocyte size was significantly reduced, and lipid accumulation was markedly decreased. Mechanistic studies revealed that, compared to the IR group, the expression of DMRT2, Drp1, and p-Drp1 was sig nificantly reversed in the IR+HMnO2, IR+DMRT2, and IR+HMnO2-DMRT2 groups. Additionally, the MitoSOX Red fluorescence signal was significantly reduced, the GSH content and SOD enzyme activity recovered, the MDA content decreased, and glucose uptake was restored (P<0.001). These findings suggest that the prepared HMnO2 DMRT2 nanoparticles may synergistically promote adipose browning by clearing oxidative stress and delivering the DMRT2 gene, exhibiting a potential regulatory role in stabilizing mitochondrial dynamics and remodeling adi pose tissue, which provides preliminary experimental evidence for targeting insulin resistance in the future.



CN
EN